mutations specified the fact that, as defined down below, CLL therapy relies within the existence or absence of those mutations. The current consensus is, in addition to clonal mutations, subclonal mutations with a variant allelic frequency ranging from 5 to ten% (and thus beneath the threshold of detection by traditional molecular tactics) may be